Developed by the Russian National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya, the drug Gam-COVID-Vak, known under the marketing name “Sputnik V”, has become one of the most popular coronavirus vaccines in the world. A message about this appeared on the official page “Sputnik V” on Twitter.
Sputnik V managed to bypass the Pfizer vaccine in popularity. The Russian drug is second only to the AstraZeneca vaccine, developed by the Anglo-Swedish company of the same name. Speaking of popularity, we mean the number of countries where the use of a particular vaccine is agreed. Thus, AstraZeneca is currently approved in 49 countries, Sputnik-V is approved for use in 45 countries, and Pfizer – in 43 countries. The Moderna vaccine is officially approved in 19 countries, and Chinese-made preparations Sinopharm, Sinovac and CanSino have been approved in 18, 16 and 4 countries, respectively. The Johnson & Johnson vaccine, developed by an American company that produces not only household chemicals, but also medicines and medical equipment, has also been approved in 4 countries.
Recall that Sputnik V is a combined vector vaccine for the prevention of COVID-19, developed by biotechnology. It became the first registered coronavirus vaccine in the world and, according to the results of the third stage of clinical trials, its effectiveness reaches 91.7%. They are vaccinated with “Sputnik-V” in two stages with a three-week interval. In addition to Russia, the domestic vaccine is used in a number of countries in Europe, the CIS, Africa and the Middle East, including Belarus, Kazakhstan, Syria, Slovakia, Hungary, Tunisia, Egypt and the United Arab Emirates. According to the stopkoronavirus.ru portal, the total population in the countries where this drug is registered exceeds 1.2 billion people.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
